Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Fermi Announces New Agreements with Investment-Grade Hyperscaler and Third Quarter 2026 Financial Results12.11.2026 13:00:00 CET | Press release
DALLAS, TX / ACCESS Newswire / November 12, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced its third quarter 2026 financial results and multiple new agreements with an investment-grade hyperscaler to advance 600 megawatts ("MW") of power capacity at Project Matador. A conference call is scheduled for 9 a.m. Eastern Time / 2 p.m. British Time today, November 12, 2026. Accompanying slides and prepared remarks can be found at https://investor.fermiamerica.com. Participation details are included in this release. "Hyperscalers want sites that are ready with permitted power, and Fermi's Project Matador is one of few that can meet that demand today," said Lee McIntire, Fermi Chief Executive Officer. "Our headstart in speed to power is a key reason an investment-grade hyperscaler has signed up for 600 megawatts and committed more than $200 million up front to accelerate construction at Project Matador with an additional $90 mi
Nexteer Announces First Share Repurchase Programme of Up to US$60 Million12.11.2026 01:40:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / November 11, 2026 / Nexteer Automotive today announced that its Board of Directors has approved, the Company's first share repurchase programme of up to US$60 million, equivalent to approximately HK$471 million. The programme reflects the Board's confidence in Nexteer's business and long-term prospects. The Group's strong liquidity position supports returning capital to shareholders while continuing to invest in the business and its future development. Disciplined Capital Allocation The programme complements Nexteer's dividend distributions and represents a further step in returning capital to shareholders. It follows the dividend paid out in July 2026 of approximately US$46 million, representing 45% of the Company's net income attributable to shareholders for the year ending December 31, 2025 -and the highest dividend payout ratio in the Company's history. Nexteer remains committed to disciplined capital allocation, balancing investment in the busines
GoodData.AI Launches the Agentic Serving Plane, a New Category of Enterprise Data Infrastructure for AI Agents10.11.2026 15:30:00 CET | Press release
SAN FRANCISCO, CA / ACCESS Newswire / November 10, 2026 / GoodData.AI, the open agentic analytics platform, today launched the Agentic Serving Plane, a governed execution layer designed for the high-concurrency, context-rich data workloads created by AI agents. The Agentic Serving Plane sits between enterprise data platforms and the applications, analytics experiences and agents that consume them. It provides workload serving, business semantics, contextual grounding, access control, and AI execution services through a common governed layer. The current enterprise data infrastructure was designed primarily for humans: occasional queries, predictable workloads, and access by known users. AI agents operate differently. A single business task can generate tens or hundreds of short-lived data operations as an agent investigates, reasons, and decides what to ask next. When many agents operate simultaneously, intermittent human querying becomes continuous, high-concurrency agentic demand. Ag
Envision Pharma Group appoints Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian10.11.2026 15:00:00 CET | Press release
FAIRFIELD, CT / ACCESS Newswire / November 10, 2026 / Envision Pharma Group (Envision), a global, technology-enabled solutions partner to the life sciences industry, has appointed Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian. Siino will lead a team providing best-in-class launch and revenue management services to the biopharma community. Pharma and biotech companies across the industry seek suppliers who can support them from their earliest stages, often before they have built in-house commercial, market access, and revenue management capabilities. Two Labs provides commercialization services and consulting support as these companies prepare for and execute successful launches; Riparian offers consulting, managed services, and technology to manage and protect revenue as their therapies reach patients. Together, Envision's Two Labs and Riparian businesses offer a single, connected solution spanning launch and beyond. Under Siino's leadership, clients wi
Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations10.11.2026 14:00:00 CET | Press release
LINCOLN, NE / ACCESS Newswire / November 10, 2026 / Securitas Healthcare, a leading provider of real-time visibility and protection solutions for the healthcare industry, today announced the next generation of its MobileView® Real-Time Location System (RTLS) platform. The expanded platform introduces MobileView Cloud, new solution capabilities, enhanced user experiences, and flexible deployment, technology, and integration options that help healthcare organizations transform real-time visibility into operational intelligence. As health systems navigate workforce shortages, capacity constraints, and growing demands for efficiency and better patient experiences, timely access to operational and clinical information has become essential to managing increasingly complex care environments. Today's RTLS platforms provide the visibility and intelligence needed to improve patient throughput, enhance safety, optimize resource utilization, and support the connected operations required to enable
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom